The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Influenza virus polymerase inhibitors in clinical development
Open accessAbstract
Purpose of review: We review antivirals inhibiting subunits of the influenza polymerase complex that are advancing in clinical development. Recent findings: Favipiravir, pimodivir, and baloxavir are inhibitory in preclinical models for influenza A viruses, including pandemic threat viruses and those resistant to currently approved antivirals, and two (favipiravir and baloxavir) also inhibit influenza B viruses. All are orally administered, although the dosing regimens vary. The polymerase basic protein 1 transcriptase inhibitor favipiravir has shown inconsistent clinical effects in uncomplicated influenza, and is teratogenic effects in multiple species, contraindicating its use in pregnancy. The polymerase basic protein 2 cap-binding inhibitor pimodivir displays antiviral effects alone and in combination with oseltamivir in uncomplicated influenza, although variants with reduced susceptibility emerge frequently during monotherapy. Single doses of the polymerase acidic protein cap-dependent endonuclease inhibitor baloxavir are effective in alleviating symptoms and rapidly inhibiting viral replication in otherwise healthy and higher risk patients with acute influenza, although variants with reduced susceptibility emerge frequently during monotherapy. Combinations of newer polymerase inhibitors with neuraminidase inhibitors show synergy in preclinical models and are currently undergoing clinical testing in hospitalized patients. Summary: These new polymerase inhibitors promise to add to the clinical management options and overall control strategies for influenza virus infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
Hayden, F. G., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M. D., Hurt, A. C., Ishida, T., Sekino, H., Yamada, K., Portsmouth, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716197 · Cited by 925
Self-citationThe cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit
Dias, A., Bouvier, D., Crépin, T., McCarthy, A. A., Hart, D. J., Baudin, F., Cusack, S., & Ruigrok, R. W. H. (2009) · Nature · doi:10.1038/nature07745 · Cited by 763
Crystal structure of an avian influenza polymerase PAN reveals an endonuclease active site
Yuan, P., Bartlam, M., Lou, Z., Chen, S., Zhou, J., He, X., Lv, Z., Ge, R., Li, X., Deng, T., et al. (2009) · Nature · doi:10.1038/nature07720 · Cited by 497
Structure of influenza A polymerase bound to the viral RNA promoter
Pflug, A., Guilligay, D., Reich, S., & Cusack, S. (2014) · Nature · doi:10.1038/nature14008 · Cited by 481
Structural insight into cap-snatching and RNA synthesis by influenza polymerase
Reich, S., Guilligay, D., Pflug, A., Malet, H., Berger, I., Crépin, T., Hart, D., Lunardi, T., Nanao, M., Ruigrok, R. W. H., et al. (2014) · Nature · doi:10.1038/nature14009 · Cited by 465
Omoto, S., Speranzini, V., Hashimoto, T., Noshi, T., Yamaguchi, H., Kawai, M., Kawaguchi, K., Uehara, T., Shishido, T., Naito, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27890-4 · Cited by 446
Characterization of H7N9 influenza A viruses isolated from humans
Watanabe, T., Kiso, M., Fukuyama, S., Nakajima, N., Imai, M., Yamada, S., Murakami, S., Yamayoshi, S., Iwatsuki-Horimoto, K., Sakoda, Y., et al. (2013) · Nature · doi:10.1038/nature12392 · Cited by 399
Noshi, T., Kitano, M., Taniguchi, K., Yamamoto, A., Omoto, S., Baba, K., Hashimoto, T., Ishida, K., Kushima, Y., Hattori, K., et al. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.10.008 · Cited by 381
The mechanism of resistance to favipiravir in influenza
Goldhill, D. H., te Velthuis, A. J. W., Fletcher, R. A., Langat, P., Zambon, M., Lackenby, A., & Barclay, W. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811345115 · Cited by 298
Cited by
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Role of favipiravir in the treatment of COVID-19
Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., & Barkate, H. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.10.069 · Cited by 462
Ge, Y., Tian, T., Huang, S., Wan, F., Li, J., Li, S., Wang, X., Yang, H., Hong, L., Wu, N., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00568-6 · Cited by 300
Critical care management of adults with community-acquired severe respiratory viral infection
Arabi, Y. M., Fowler, R., & Hayden, F. G. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05943-5 · Cited by 260
Self-citation
Metadata
- Authors
- Hayden, F. G., & Shindo, N.
- Venue
- Current Opinion in Infectious Diseases
- Published
- 2019-04
- Volume
- 32
- Issue
- 2
- Pages
- 176-186
- ISSN
- 0951-7375 (ISSN-L)
- 1473-6527
- OpenAlex
- W2911505242
- Cited by
- 254
- References
- 24
- FWCI
- 28.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influenza virus polymerase inhibitors in clinical development. https://app.cochat.ai/papers/10.1097/qco.0000000000000532
- The paper
- Hayden, F. G., & Shindo, N. (2019). Influenza virus polymerase inhibitors in clinical development. Current Opinion in Infectious Diseases. https://doi.org/10.1097/qco.0000000000000532
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.